ISS staging Introduction (What it is)
ISS staging is a clinical staging system most commonly used for multiple myeloma.
It groups myeloma into broad risk categories using simple blood test results.
It helps clinicians describe disease severity in a standardized way.
It is often used at diagnosis and when discussing prognosis and treatment planning.
Why ISS staging used (Purpose / benefits)
Staging is the process of describing how extensive a cancer is and how it is behaving. In solid tumors, staging often relies on tumor size and spread (such as TNM staging). Multiple myeloma is a blood cancer of plasma cells in the bone marrow, so “size” and “spread” are not measured the same way. ISS staging helps solve this problem by using laboratory markers that reflect overall disease burden and the body’s condition.
ISS staging is used because it can:
- Standardize communication across clinicians, hospitals, and research studies.
- Support prognosis discussions by placing patients into broad outcome groups (prognosis varies by biology and treatment, so staging is one part of the picture).
- Guide risk-adapted thinking in treatment planning, such as how closely to monitor and which additional tests may be important.
- Enable fair comparisons in research, including clinical trial eligibility and stratification (balancing study groups by risk).
- Provide a baseline for tracking changes over time alongside symptoms, imaging, and other lab results.
ISS staging does not replace clinical judgment, imaging, bone marrow testing, or genetic risk assessment. Instead, it provides a widely used framework that can be combined with other information.
Indications (When oncology clinicians use it)
Clinicians commonly use ISS staging in situations such as:
- At initial diagnosis of symptomatic multiple myeloma to document baseline risk
- When reviewing blood test patterns that suggest myeloma activity or burden
- During treatment planning discussions, including consideration of intensity and monitoring needs
- For clinical trial enrollment or research reporting that requires standardized staging
- When comparing response and outcomes across groups in registries or quality programs
- When counseling about the overall clinical picture alongside imaging, bone marrow findings, and cytogenetics
Contraindications / when it’s NOT ideal
ISS staging is not “dangerous,” but it can be less suitable or less informative in some contexts, including:
- Cancers other than multiple myeloma, where other staging systems are used (for example, TNM for many solid tumors)
- Conditions that alter the key lab markers for reasons not directly related to myeloma burden (interpretation may be less straightforward and depends on the case)
- Situations where genetic risk dominates decision-making, because ISS staging alone does not include myeloma cytogenetics
- Early or precursor plasma cell disorders (such as some cases of smoldering disease), where risk models may differ and staging may be described differently
- Relapsed/refractory myeloma, where clinicians often reassess risk using a broader set of factors beyond the original ISS staging category
In these situations, clinicians may emphasize other frameworks (such as revised staging approaches, cytogenetic risk, imaging findings, or disease response measures) to better capture current risk.
How it works (Mechanism / physiology)
ISS staging is not a treatment and has no “mechanism of action” in the way a drug or radiation therapy does. Instead, it is a classification system that uses lab-based signals of disease severity to place myeloma into stages.
At a high level, ISS staging reflects two core ideas:
-
Myeloma burden and biology influence measurable blood markers.
Myeloma cells can increase overall protein production and interact with the bone marrow and immune system. Disease burden and its systemic effects are reflected indirectly through certain laboratory values. -
The patient’s overall physiological state matters.
ISS staging incorporates markers that relate to nutrition/inflammation and the body’s response to disease.
ISS staging is primarily based on serum beta-2 microglobulin and serum albumin:
- Beta-2 microglobulin is a protein associated with cell turnover and is influenced by kidney handling. In myeloma, higher levels often correlate with higher tumor burden and/or reduced kidney function.
- Albumin is a major blood protein and can be affected by inflammation, nutrition, and systemic illness. Lower levels can correlate with a more active disease environment.
ISS staging divides myeloma into three stages (Stage I, II, and III) based on combinations of these lab results. Generally, higher beta-2 microglobulin and lower albumin correspond to higher stage, but clinicians interpret results in context.
Because ISS staging is a classification rather than an intervention:
- Onset and duration do not apply the way they would for therapy.
- Reversibility is better thought of as whether the underlying disease and contributing conditions improve with treatment and supportive care, which can change lab values over time.
ISS staging Procedure overview (How it’s applied)
ISS staging is not a procedure like surgery. It is a structured way of using clinical information—primarily blood tests—to assign a stage. A typical high-level workflow looks like this:
-
Evaluation / exam
Clinicians assess symptoms (such as fatigue, bone pain, infections), physical findings, and overall function, and review medical history. -
Imaging / biopsy / labs
– Blood tests include albumin and beta-2 microglobulin (core to ISS staging), and often additional tests to characterize myeloma and organ impact.
– Urine testing may be used to evaluate protein production patterns.
– Bone marrow biopsy helps confirm diagnosis and evaluate plasma cell involvement.
– Imaging may be used to evaluate bone disease or other myeloma-related findings. -
Staging
ISS staging is assigned as Stage I, II, or III based on the relevant lab results at (or near) diagnosis, using established criteria. -
Treatment planning
The stage is considered alongside other key features, such as genetic findings, kidney function, anemia, calcium level, bone disease, and patient goals. -
Intervention / therapy
Treatment choices vary by clinician and case and may include systemic therapy and supportive care for bone health, infection prevention, and symptom control. -
Response assessment
Response is typically monitored with repeat labs, symptom review, and sometimes repeat imaging or bone marrow testing, depending on the clinical situation. -
Follow-up / survivorship
Ongoing monitoring focuses on disease control, side-effect management, rehabilitation, and long-term health maintenance as appropriate.
Types / variations
ISS staging is the “classic” International Staging System used in multiple myeloma, but real-world care often includes related or expanded approaches.
Common variations and related concepts include:
-
ISS staging (International Staging System)
Uses key blood markers (albumin and beta-2 microglobulin) to categorize myeloma into three stages. -
Revised staging approaches (commonly referred to as revised ISS frameworks)
Many clinical settings use staging that adds additional prognostic factors—often including LDH (lactate dehydrogenase) and high-risk cytogenetic abnormalities identified by tests such as FISH (fluorescence in situ hybridization). These additions aim to better capture tumor biology beyond the two lab values in ISS staging. -
Other myeloma classification and risk tools
Some clinicians reference additional systems or risk stratification frameworks that incorporate genetics, response depth, and imaging findings. These are not interchangeable with ISS staging, but they can complement it. -
Setting-based variation in use (community vs specialty centers; inpatient vs outpatient)
ISS staging is widely applicable because it relies on common blood tests. More specialized centers may more consistently pair it with genetic testing and advanced response measures, depending on resources and clinical goals.
ISS staging is specific to hematologic malignancy care (myeloma) rather than solid-tumor oncology, where staging is typically anatomy-based.
Pros and cons
Pros:
- Uses widely available blood tests, making it practical in many care settings
- Provides a simple, standardized way to describe baseline disease severity
- Helps with prognosis framing at a population level (individual outcomes vary)
- Supports clinical trial design and comparison across studies
- Can be combined with other data (genetics, imaging, response) for a fuller picture
- Easy to document and explain as Stage I–III categories
Cons:
- Does not directly measure genetics or high-risk cytogenetics, which can strongly affect prognosis
- Can be influenced by non-myeloma factors that alter albumin or beta-2 microglobulin (interpretation depends on the clinical context)
- Offers broad categories and may not capture nuanced risk differences within a stage
- Not designed to be a standalone decision tool for choosing specific therapies
- May be less informative in relapsed disease, where current biology and treatment history matter
- Can be confusing when mixed with other systems (ISS staging vs revised approaches vs other risk models)
Aftercare & longevity
ISS staging itself does not require aftercare because it is not a treatment. However, the stage contributes to the overall clinical picture, which can influence how clinicians think about monitoring intensity and supportive care needs.
Factors that commonly affect outcomes and longer-term disease control in myeloma include:
-
Cancer biology
Cytogenetic and molecular risk features can change expected behavior even within the same ISS staging category. -
Disease burden and organ involvement
Kidney function, anemia, bone disease, calcium abnormalities, and infection history can shape both treatment tolerance and recovery needs. -
Depth and durability of response to therapy
How well myeloma markers improve and how long control lasts vary by clinician and case, treatment approach, and biology. -
Treatment tolerance and side-effect management
Dose adjustments, supportive medications, bone health strategies, and symptom management can influence quality of life and the ability to stay on therapy. -
Follow-up structure
Ongoing monitoring typically includes periodic labs and clinical assessments. The exact schedule varies by clinician and phase of care. -
Comorbidities and functional status
Heart, lung, kidney, neurologic, or metabolic conditions can affect treatment choices and recovery. -
Rehabilitation and survivorship support
Physical therapy, pain management, nutrition support, and psychosocial care can be important, especially when bone disease or fatigue affects daily function.
In practice, ISS staging is one input among many used to personalize follow-up plans and supportive care priorities.
Alternatives / comparisons
ISS staging is a staging system, not a therapy, so “alternatives” usually mean other ways of classifying risk and extent of disease. Common comparisons include:
-
ISS staging vs TNM staging
TNM is anatomy-based and common in solid tumors (tumor size, lymph nodes, metastasis). ISS staging is lab-based and tailored to myeloma, which is a systemic bone marrow disease. -
ISS staging vs Durie–Salmon staging (historical/parallel concept)
Some older myeloma staging approaches place more emphasis on clinical findings such as bone lesions, hemoglobin, and calcium. ISS staging is generally simpler and relies on fewer, widely available lab measures. -
ISS staging vs revised ISS-style systems
Revised approaches commonly add LDH and cytogenetic risk. This can better reflect aggressive biology in some patients, but it requires additional testing and standardized interpretation. -
ISS staging vs response-based assessment
Staging describes baseline risk; response assessment evaluates how well treatment is working over time using myeloma markers and clinical status. Both are used, but they answer different questions. -
ISS staging in care planning vs clinical trials
In routine care, ISS staging is used alongside patient-specific factors and clinician judgment. In trials, it may also be used to balance study groups, with additional inclusion criteria that vary by study. -
Observation/active surveillance (in precursor conditions)
For some precursor plasma cell disorders, clinicians may monitor rather than treat immediately. This is not an “alternative” to ISS staging for active myeloma, but it reflects that different disease states use different risk tools and decision pathways.
ISS staging Common questions (FAQ)
Q: Is ISS staging the same as “cancer stage” in other cancers?
ISS staging is a form of cancer staging, but it is designed specifically for multiple myeloma. Many other cancers use anatomy-based staging, while ISS staging uses blood markers that correlate with disease burden and systemic effects.
Q: Does ISS staging require a biopsy or surgery?
ISS staging itself is based on blood test results and does not require surgery. A bone marrow biopsy and imaging are commonly part of the overall myeloma workup, but they are separate from the ISS staging calculation.
Q: Is ISS staging painful or does it need anesthesia?
ISS staging typically relies on routine blood draws, which may cause brief discomfort. Anesthesia is not needed for staging itself, though other diagnostic procedures (like bone marrow biopsy) may involve local anesthetic or sedation depending on the setting.
Q: Are there side effects from ISS staging?
ISS staging has no direct side effects because it is a classification method, not a treatment. Any risks are mainly related to the blood draw process, which is generally low risk.
Q: How long does it take to get an ISS staging result?
Timing depends on how quickly the relevant lab results return and when the care team formally reviews them. In many settings, it can be assigned once albumin and beta-2 microglobulin results are available, but the overall diagnostic workup may take longer.
Q: Will ISS staging determine which treatment I receive?
ISS staging can inform overall risk discussion, but it is usually not the only factor in treatment planning. Clinicians typically also consider genetic risk tests, organ function (especially kidneys), symptoms, imaging findings, and patient preferences.
Q: How much does ISS staging cost?
There is no separate “ISS staging fee” in most settings; costs relate to office visits and laboratory testing. Out-of-pocket costs vary by insurance coverage, location, and which additional tests are ordered.
Q: Can ISS staging change over time?
ISS staging is commonly documented at diagnosis, using baseline lab values. Lab values can change with treatment or changes in health status, but clinicians may use additional tools—such as revised risk models and response criteria—to describe current status over time.
Q: Will ISS staging affect my ability to work or be active?
ISS staging itself does not limit activity because it is not a treatment. Work and activity levels are more often influenced by symptoms (such as fatigue or bone pain), anemia, bone disease risk, treatment side effects, and overall health.
Q: Does ISS staging say anything about fertility or pregnancy?
ISS staging does not directly address fertility. Fertility considerations are more closely tied to specific myeloma treatments and overall health status, and they are typically discussed separately as part of treatment planning.